> top > projects > Inflammaging > docs > PubMed:33008453 > annotations
Inflammaging  

PubMed:33008453 JSONTXT 20 Projects

Annnotations TAB TSV DIC JSON TextAE Lectin_function IAV-Glycan

Id Subject Object Predicate Lexical cue
T1 0-95 Sentence denotes Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia.
T1 0-95 Sentence denotes Severe COVID-19 virus reactivation following treatment for B cell acute lymphoblastic leukemia.
T2 96-223 Sentence denotes SARS-CoV-2 has infected millions of people worldwide, but little is known at this time about second infections or reactivation.
T2 96-223 Sentence denotes SARS-CoV-2 has infected millions of people worldwide, but little is known at this time about second infections or reactivation.
T3 224-428 Sentence denotes Here, we report a case of a 55-year-old female undergoing treatment for CD20+ B cell acute lymphoblastic leukemia who experienced a viral reactivation after receiving rituximab, cytarabine, and dasatinib.
T3 224-428 Sentence denotes Here, we report a case of a 55-year-old female undergoing treatment for CD20+ B cell acute lymphoblastic leukemia who experienced a viral reactivation after receiving rituximab, cytarabine, and dasatinib.
T4 429-609 Sentence denotes She was initially hospitalized with COVID-19 in April and developed a high antibody titer with two negative nasal polymerase chain reaction (PCR) swabs for SARS-CoV-2 on discharge.
T4 429-609 Sentence denotes She was initially hospitalized with COVID-19 in April and developed a high antibody titer with two negative nasal polymerase chain reaction (PCR) swabs for SARS-CoV-2 on discharge.
T5 610-726 Sentence denotes After recovery, she resumed treatment in June for her leukemia, which included rituximab, cytarabine, and dasatinib.
T5 610-726 Sentence denotes After recovery, she resumed treatment in June for her leukemia, which included rituximab, cytarabine, and dasatinib.
T6 727-812 Sentence denotes She promptly lost her COVID-19 antibodies, and her nasal PCR turned positive in June.
T6 727-812 Sentence denotes She promptly lost her COVID-19 antibodies, and her nasal PCR turned positive in June.
T7 813-1039 Sentence denotes She developed a severe COVID-19 pneumonia with lymphopenia, high inflammatory markers, and characteristic bilateral ground-glass opacities on chest CT, requiring high-flow nasal cannula and transfer to the intensive care unit.
T7 813-1039 Sentence denotes She developed a severe COVID-19 pneumonia with lymphopenia, high inflammatory markers, and characteristic bilateral ground-glass opacities on chest CT, requiring high-flow nasal cannula and transfer to the intensive care unit.
T8 1040-1140 Sentence denotes She received steroids, anticoagulation, and convalescent plasma, and within 48 h she was off oxygen.
T8 1040-1140 Sentence denotes She received steroids, anticoagulation, and convalescent plasma, and within 48 h she was off oxygen.
T9 1141-1204 Sentence denotes She was discharged home in stable condition several days later.
T9 1141-1204 Sentence denotes She was discharged home in stable condition several days later.
T10 1205-1422 Sentence denotes Given the short time frame from leukemia treatment to PCR positivity and the low case rate in mid-June in New York City, reinfection appears to have been unlikely and SARS-CoV-2 reactivation is a possible explanation.
T10 1205-1422 Sentence denotes Given the short time frame from leukemia treatment to PCR positivity and the low case rate in mid-June in New York City, reinfection appears to have been unlikely and SARS-CoV-2 reactivation is a possible explanation.
T11 1423-1665 Sentence denotes This case illustrates the risks of treating recently recovered COVID-19 patients with immunosuppressive therapy, particularly lymphocyte- and antibody-depleting therapy, and raises new questions about the potential of SARS-CoV-2 reactivation.
T11 1423-1665 Sentence denotes This case illustrates the risks of treating recently recovered COVID-19 patients with immunosuppressive therapy, particularly lymphocyte- and antibody-depleting therapy, and raises new questions about the potential of SARS-CoV-2 reactivation.